ArticleAntimicrobial agents and chemotherapy2007
Caspofungin in combination with amphotericin B against Candida parapsilosis.
Article in Antimicrobial agents and chemotherapy, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 37 citations in OpenAlex.
- Randomized comparison of safety and pharmacokinetics of caspofungin, liposomal amphotericin B, and the combination of both in allogeneic hematopoietic stem cell recipients.Antimicrobial agents and chemotherapy · 2010Trial
- Synergistic eradication ofFrontiers in medicine · 2026Article
- In Vitro Activity of Isavuconazole and Amphotericin B in Association against Mucorales.Pathogens (Basel, Switzerland) · 2023Article
- Antifungal Combinations againstJournal of fungi (Basel, Switzerland) · 2022Review
- Multicenter Collaborative Study of the Interaction of Antifungal Combinations againstJournal of fungi (Basel, Switzerland) · 2022Article
- Cecropin D-derived synthetic peptides in the fight againstFrontiers in microbiology · 2022Article
- In Vitro Characterization of Twenty-One Antifungal Combinations against Echinocandin-Resistant and -SusceptibleJournal of fungi (Basel, Switzerland) · 2021Article
- Candida parapsilosis: from Genes to the Bedside.Clinical microbiology reviews · 2019Review
- Article
- Outcome of Candida Parapsilosis Complex Infections Treated with Caspofungin in Children.Mediterranean journal of hematology and infectious diseases · 2016Article
- Anidulafungin versus caspofungin in a mouse model of candidiasis caused by anidulafungin-susceptible Candida parapsilosis isolates with different degrees of caspofungin susceptibility.Antimicrobial agents and chemotherapy · 2014Article
- Novel method for evaluating in vitro activity of anidulafungin in combination with amphotericin B or azoles.Journal of clinical microbiology · 2012Article
- Broth microdilution and time-kill testing of Caspofungin, voriconazole, amphotericin B and their combinations against clinical isolates of Candida krusei.Mycopathologia · 2012Article
- Multilaboratory testing of two-drug combinations of antifungals against Candida albicans, Candida glabrata, and Candida parapsilosis.Antimicrobial agents and chemotherapy · 2011Article
- Synergistic activities of three triazoles with caspofungin against Candida glabrata isolates determined by time-kill, Etest, and disk diffusion methods.Antimicrobial agents and chemotherapy · 2010Article
- Antifungal activity of caspofungin in combination with amphotericin B against Candida glabrata: comparison of disk diffusion, Etest, and time-kill methods.Antimicrobial agents and chemotherapy · 2009Article
- Candida parapsilosis, an emerging fungal pathogen.Clinical microbiology reviews · 2008Review
- In vitro interactions of micafungin with amphotericin B against clinical isolates of Candida spp.Antimicrobial agents and chemotherapy · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Candida parapsilosis has emerged as an important nosocomial pathogen. In the present study, a checkerboard broth microdilution method was performed to investigate the in vitro activities of caspofungin (CAS) in combination with amphotericin B (AMB) against three clinical isolates of C. parapsilosis. Although there was a significant reduction of the MIC of one or both drugs used in combination, an indifferent interaction (fractional inhibitory concentration index greater than 0.50 and less than or equal to 4.0) was observed in 100% of cases. This finding was confirmed by killing curve studies. By a disk diffusion assay, the halo diameters produced by antifungal agents in combination were often significantly greater than those produced by each drug alone. Antagonism was never observed. In a murine model of systemic candidiasis, CAS at either 0.25 or 1 mg/kg/day combined with AMB at 1 mg/kg/day was significantly more effective than each single drug at reducing the colony counts in kidneys. Higher doses of the echinocandin (i.e., 5 and 10 mg/kg/day) combined with the polyene did not show any advantage over CAS alone. Overall, our study showed a positive interaction of CAS and AMB against C. parapsilosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.